Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Commentary|Articles|July 29, 2026
Oncology Experts Review Key ASCO 2026 Data for Daraxonrasib and Other Novel Therapies in GI Cancers
Author(s)Chris Ryan
Fact checked by: Ashling Wahner
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
While data for daraxonrasib in patients with pretreated metastatic pancreatic ductal adenocarcinoma stole the show at the
Related to this article
During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Trine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer/
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.
Advertisement
Advertisement